Sector News

Celldex to ax 20% of staff after midstage glembatumumab rout

April 26, 2018
Life sciences

Celldex Therapeutics ditched its glembatumumab vedotin program last week after it failed a phase 2 study in triple-negative breast cancer. Now, the company is laying off 41 employees and choosing not to fill 18 open positions to cut costs and stay afloat.

The reduction will leave the company with 148 employees and come to about $1.3 million in severance-related costs, Celldex said in an SEC filing Tuesday. In addition to slashing operating costs, the move will also “better align its workforce with the needs of its business,” the company said.

New Jersey-based Celldex hit its first major roadblock in 2016, when its cancer vaccine Rintega failed a phase 3 glioblastoma trial. Once predicted to become the second cancer vaccine to earn approval in the U.S. after Provenge, the candidate did not improve survival, leading Celldex to end the trial. It turned to glembatumumab vedotin (glemba), the most advanced asset in its pipeline.

But that blew up too—nearly two years later, history repeated itself and the once-promising glemba also failed to improve survival over Genentech’s Xeloda in patients with metastatic triple-negative breast cancer. Celldex discontinued the program and started “evaluating our operational and workforce needs to extend our financial resources and direct them to continued pipeline advancement,” said CEO Anthony Marucci at the time.

Now, Celldex is left to pick up the pieces with what’s left of its pipeline. Varlilumab, a CD27 agonist, is in a phase 2 study in combination with Bristol-Myers’ Opdivo, with data expected to read out this year. And a phase 2 trial of CDX-3379, an ErbB3 inhibitor, in tandem with Eli Lilly’s Erbitux is set to finish enrolling in the third quarter. That leaves a CD40 agonist and a dendritic cell mobilizer, which are both in phase 1.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

May 27, 2023

Positive opinion for Novo Nordisk’s Sogroya

Life sciences

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.

May 27, 2023

Medtronic acquires insulin patch pump maker EOFlow for $738M amid new MiniMed rollout

Life sciences

Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.

May 27, 2023

Apnimed cracks sleep apnea puzzle, hits primary goal in phase 2 study

Life sciences

Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”

How can we help you?

We're easy to reach